Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A. Beck, Arsalan Shabbir, Ryszard Galus et al.|American Journal of Clinical Dermatology|2022Cited by 104
Dupilumab in Adults With Moderate to Severe Atopic DermatitisLisa A. Beck, Arsalan Shabbir, Robert Bissonnette et al.|JAMA Dermatology|2024Cited by 64